Sign In

Lydia The, Ph.D.

VP Strategy & Growth at Eli Lilly and Company

Lydia The, Ph.D. is a highly accomplished professional currently serving as the VP of Strategy & Growth at Eli Lilly and Company's Business Development function.1 She joined Eli Lilly in this role in 2023, after a successful career at McKinsey & Company.12

Professional Experience

Prior to her current position, Lydia spent 9 years at McKinsey & Company, where she held the position of Partner in the Silicon Valley office.1 Her transition to Eli Lilly was announced in January 2023, when she joined the Corporate Business Development team to lead Strategy and Growth.2

Education

Lydia The holds impressive academic credentials:

  • Ph.D. in Molecular and Cell Biology from UC Berkeley
  • Bachelor of Arts (BA) in Biology from Swarthmore College1

Honors and Awards

Her academic achievements have been recognized with notable honors:

  • National Science Foundation Graduate Research Fellowship
  • International Forum for the Study of Itch Handwerker Prize1

Location

Lydia is based in Millbrae, California, United States.1

Lydia The's career trajectory showcases a strong background in strategy, business development, and life sciences, making her well-suited for her leadership role at Eli Lilly and Company.

Highlights

May 17 · linkedin

Today is Neurofibromatosis Awareness Day.

We were overjoyed to welcome our first child Lark Juliet (LJ) Huang in December. It was a long journey to get here. But after 5 rounds of IVF, 5 failed transfers, and 3 surrogates, it seemed we could finally breathe a sigh of relief. She was here. And she was perfect.

At her 2-week check-up, our pediatrician pointed out her large birthmarks known as Café-Au-Lait spots. And then began a harrowing few weeks of seeing a dermatologist, an ophthalmologist, a genetics counselor, taking samples for genetic testing, and a long wait to confirm what our pediatrician suspected. LJ has a sporadic case (not inherited) of Neurofibromatosis 1 (NF1).

NF1 is a rare (1 in 2500 births) genetic disease caused by a mutation in the tumor suppressor gene neurofibromin. It causes uncontrolled tumor growth. There is an enormous range in severity. Some patients never realize they have it. Others have tumors that can be physically disfiguring (50% plexiform neurofibromas), or tumors that transform into deadly cancers (~10% malignant peripheral nerve sheath tumors), or tumors that can lead to vision loss (15% optic gliomas), or cognitive defects / learning disability / autism spectrum disorders (80%), or bone abnormalities that can require amputation (5% pseudoarthrosis). It’s impossible to predict how NF1 will affect LJ or other patients, when and how bad.

There is no cure for NF and it is woefully understudied and underfunded, despite being more common than cystic fibrosis, Duchenne muscular dystrophy and Huntington’s. But we have hope because the first drug for a NF1 associated tumor was approved in 2020. And there are scientists dedicated to better understanding the biology and advancing other therapies. And there is a fantastic nonprofit @Children’s Tumor Foundation (CTF) that supports research to end NF.

We were able to join CTF’s NF Summit for patients in April, where we had the chance to meet other NF patients. While no one would choose to be part of the rare disease community, we’re grateful for how warm and supportive it is. In this scary moment, we decided to pour our energy and efforts into CTF, with the hope that they can fill the gap in funding needed to bring new therapies to NF patients. And hopefully one day a cure.

This month during NF Awareness Month, we are fundraising to support CTF. We would be grateful for any amount you can contribute.

May 4 · linkedin

In my last white paper before leaving McKinsey & Company, we explored pipeline herding around a small set of highly attractive targets. The average number of assets per target more than doubled in the last 20 years, and that trend was largely driven by oncology. Read more in our paper in #Nature Reviews Drug Discovery, published with Christian Fougner, Julie Cannon, M.D., Olivier Leclerc and Jeff Smith.

Related Questions

What are some of Lydia The's key achievements at Eli Lilly and Company?
How did Lydia The transition from McKinsey & Company to Eli Lilly and Company?
What specific strategies has Lydia The implemented at Eli Lilly and Company?
What is Lydia The's educational background and how has it influenced her career?
What awards and recognitions has Lydia The received in her career?
Lydia The, Ph.D.
Lydia The, Ph.D., photo 1
Lydia The, Ph.D., photo 2
Add to my network

Experience

VP Strategy & Growth at Eli Lilly and Company (2023 - Present)
Partner at McKinsey & Company (2014 - 2023)

Education

Ph.D. in Molecular and Cell Biology from UC Berkeley; BA in Biology from Swarthmore College

Location

Millbrae, California, United States